Affordable Access

Publisher Website

Discovery of new inhibitors of aldo-keto reductase 1C1 by structure-based virtual screening

Authors
Journal
Molecular and Cellular Endocrinology
0303-7207
Publisher
Elsevier
Publication Date
Volume
301
Identifiers
DOI: 10.1016/j.mce.2008.08.002
Keywords
  • Akr1C1 Inhibitors
  • Virtual High-Throughput Screening
  • Nci “Diversity Set”
  • Ehits
Disciplines
  • Design
  • Philosophy

Abstract

Abstract Aldo-keto reductase 1C1 is a hydroxysteroid dehydrogenase that inactivates progesterone by converting it to 20α-hydroxyprogesterone. It also inactivates 3α,5α-tetrahydroprogesterone, an allosteric modulator of the γ-aminobutyric acid receptor that has anaesthetic, analgesic, anxiolytic and anti-convulsant effects. Inhibitors of aldo-keto reductase 1C1 are thus very interesting as potential agents for the treatment of endometrial cancer, premenstrual syndrome, catamenial epilepsy, and depressive disorders, and for the maintenance of pregnancy. We have used the molecular docking program eHiTS for virtual screening of 1990 compounds from the National Cancer Institute “Diversity Set”. Fifty compounds with the highest predicted binding energies were then evaluated in vitro. Three structurally diverse hits were obtained that inhibit aldo-keto reductase 1C1 in the low micromolar range of IC 50 values. These hits represent promising starting points for structural optimization in hit-to-lead development.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Selective inhibitors of aldo-keto reductases AKR1C...

on Journal of Medicinal Chemistry Sep 13, 2012

Inhibitors of aldo-keto reductases AKR1C1-AKR1C4.

on Current Medicinal Chemistry 2011

Ruthenium complexes as inhibitors of the aldo-keto...

on Chemico-Biological Interaction... Jun 05, 2015

Discovery of new inhibitors of D-alanine:D-alanine...

on Journal of Medicinal Chemistry Dec 11, 2008
More articles like this..